Breaking Finance News

Morgan Stanley downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Equal Weight in a report released today.

Morgan Stanley has downgraded Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to Equal Weight in a report released on Friday October 07, 2016.

Previously on 10/06/2016, FBR & Co. reported about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) lowered the target price from $180.00 to $100.00. At the time, this indicated a possible upside of 0.42%.

Yesterday Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded -2.38% lower at $36.21. The company’s 50-day moving average is $71.80 and its 200-day moving average is $66.24. The last stock close price is down -46.64% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 586,681 shares of the stock were exchanged, down from an average trading volume of 911,452

See Chart Below

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. has a 52 week low of $35.23 and a 52 week high of $110.75 The company’s market cap is currently $0.

In addition to Morgan Stanley reporting its target price, a total of 11 firms have reported on the stock. The consensus target price is $117.09 with 3 firms rating the stock a strong buy, 8 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *